Colorectal Neoplasms Malignant
33
10
12
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.0%
1 terminated out of 33 trials
88.9%
+2.3% vs benchmark
3%
1 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (33)
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Early Detection of Advanced Adenomas and Colorectal Cancer
Early Onset Colorectal Cancer Detection
CIRSE Emprint Microwave Ablation Registry
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
Smart Measurement of Circulating Tumor DNA
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
The COLON Study: Colorectal Cancer Cohort
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Postoperative Effects of Different Enterostomy Approaches